Immune Design Corp (NASDAQ:IMDZ) shares were down 6.3% during trading on Monday . The company traded as low as $3.70 and last traded at $3.70. Approximately 594,847 shares changed hands during mid-day trading, an increase of 90% from the average daily volume of 313,581 shares. The stock had previously closed at $3.95.

A number of research analysts recently commented on IMDZ shares. Wells Fargo & Company downgraded shares of Immune Design from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $29.00 to $10.00 in a report on Tuesday, October 17th. ValuEngine lowered shares of Immune Design from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 21st. Zacks Investment Research lowered shares of Immune Design from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Royal Bank of Canada assumed coverage on shares of Immune Design in a research report on Thursday, September 14th. They issued an “outperform” rating and a $20.00 price objective on the stock. Finally, Cowen reissued a “buy” rating on shares of Immune Design in a research report on Monday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $13.19.

Immune Design (NASDAQ:IMDZ) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.11. Immune Design had a negative net margin of 619.62% and a negative return on equity of 68.69%. The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.62 million. sell-side analysts anticipate that Immune Design Corp will post -1.89 EPS for the current fiscal year.

In other news, major shareholder Leo Guthart acquired 10,000 shares of Immune Design stock in a transaction that occurred on Thursday, October 19th. The shares were bought at an average cost of $6.09 per share, with a total value of $60,900.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Peter Svennilson bought 2,681,000 shares of Immune Design stock in a transaction dated Friday, October 27th. The shares were bought at an average cost of $4.10 per share, for a total transaction of $10,992,100.00. The disclosure for this purchase can be found here. Insiders purchased a total of 5,300,000 shares of company stock worth $21,874,900 over the last three months. 20.70% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of the company. Dimensional Fund Advisors LP increased its position in shares of Immune Design by 9.3% during the second quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock worth $184,000 after acquiring an additional 1,600 shares during the period. California State Teachers Retirement System increased its position in shares of Immune Design by 8.3% during the second quarter. California State Teachers Retirement System now owns 30,174 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 2,300 shares during the period. Trexquant Investment LP increased its position in shares of Immune Design by 15.5% during the second quarter. Trexquant Investment LP now owns 31,152 shares of the biotechnology company’s stock worth $304,000 after acquiring an additional 4,174 shares during the period. Teachers Advisors LLC increased its position in shares of Immune Design by 23.0% during the second quarter. Teachers Advisors LLC now owns 27,691 shares of the biotechnology company’s stock worth $270,000 after acquiring an additional 5,181 shares during the period. Finally, Rhumbline Advisers increased its position in shares of Immune Design by 53.9% during the second quarter. Rhumbline Advisers now owns 19,694 shares of the biotechnology company’s stock worth $192,000 after acquiring an additional 6,896 shares during the period. 29.38% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Immune Design (IMDZ) Stock Price Down 6.3%” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/immune-design-imdz-stock-price-down-6-3/1761165.html.

Immune Design Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with Analyst Ratings Network's FREE daily email newsletter.